Arcus Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net income (loss) | $(307) | $(267) | $53 |
| Other comprehensive income (loss) | 7 | (6) | (1) |
| Comprehensive income (loss) | $(300) | $(273) | $52 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.